Gail H. Cassell, PhD, DSc (hon) Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, IN
Correspondence: Gail H. Cassell, PhD, DSc (hon), Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; G.cassell@Lilly.com
Acknowledgment: The author gratefully acknowledges helpful discussions with H. Heath, A. Norris, L.E. Van Campen, M.C. Jones, G. Geipel, and S.M. Paul of Eli Lilly and Company; E. Holmes of the University of California, San Diego; and M.G. Edwards of Recombinant Capital.
Dr. Cassell reported that she has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article apart from her employment with Eli Lilly and Company, through which she receives a salary, grant/research support, and stock options.
ABSTRACT
Industry, academia, and government have developed highly interwoven relationships in the pursuit of biomedical research. Establishing and maintaining boundaries among the public and private sectors at both the institutional level and the individual level is critical to protect core scientific values, preserve innovation, and allow product development to thrive. This article reviews principles that guide the interactions of these Biomdifferent sectors, sharing principles in place at Eli Lilly and Company as an example.
